Pharma Startup Executives Must Fight Trimmed SEC Fraud Suit

In a recent Bloomberg Law article, partner and Financial and Regulatory Litigation group co-chair Paul Kisslinger commented on a federal court ruling that dismissed SEC scheme liability claims against his client in a digital pharmacy fraud case involving Medly Health Inc.

He highlighted the court's dismissal of the claims, characterizing the decision as part of a broader judicial trend reining in the SEC's expansive use of scheme claims to target individuals who could not be sued directly.